Methotrexate-Induced Nasal Septal Perforation.
A 58-year-old woman with a 31-year history of Hailey-Hailey (HH) disease that was refractory to treatment with mycophenolate mofetil, cyclosporine, dapsone, sulfasalazine, topical/oral antibiotics, and topical/oral steroids presented for alternative treatment options. Active erythematous, malodorous, eroded, and crusted plaques were present in the axillae, inframammary region, groin, and back (Figure 1). The patient had an undulant course, with acute exacerbations and partial remissions. During a 3-year period, she was prescribed oral methotrexate at a dose of 10 mg to 15 mg per week with daily oral folic acid (1 mg) supplementation, except on the day she took methotrexate. Oral clarithromycin and prednisone were also used intermittently for antibacterial and anti-inflammatory effects.
University of Chicago Pritzker School of Medicine, Section of Dermatology, Chicago, IL.
Edidiong Ntuen
EN
Kaminska
University of Chicago Pritzker School of Medicine, Chicago, IL.
Freda
F
Sansaricq
University of Chicago Pritzker School of Medicine, Section of Dermatology, Chicago, IL; vrosic@medicine.bsd.uchicago.edu.
Vesna
V
Petronic-Rosic
D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects*; D008875:Middle Aged; D061270:Nasal Septal Perforation / Q000139:chemically induced*; D016506:Pemphigus, Benign Familial / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D003879:Dermatologic Agents; D017291:Clarithromycin; D011241:Prednisone; D008727:Methotrexate